Henoch–Schönlein purpura (HSP) and high-dose immunoglobulin treatment in patient with familiar prostatic adenocarcinoma

Małgorzata Sobieszczańska, Sławomir Tubek, Dagmara Poplica, Anna Grabelus & Jacek Pawełczak

Department of Pathophysiology; Medical University; Wrocław, Poland
Department of Internal Diseases; Voivodship Hospital; Opole, Poland

Published online: 14 Apr 2014.

To cite this article: Małgorzata Sobieszczańska, Sławomir Tubek, Dagmara Poplica, Anna Grabelus & Jacek Pawełczak (2014) Henoch–Schönlein purpura (HSP) and high-dose immunoglobulin treatment in patient with familiar prostatic adenocarcinoma, Human Vaccines & Immunotherapeutics, 10:2, 358-359, DOI: 10.4161/hv.27012

To link to this article: http://dx.doi.org/10.4161/hv.27012

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Any substantial or systematic reproduction, redistribution, reselling, loan, sub-licensing, systematic supply, or distribution in any form to anyone is expressly forbidden. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions
Henoch–Schönlein purpura (HSP) and high-dose immunoglobulin treatment in patient with familiar prostatic adenocarcinoma

Małgorzata Sobieszczanka1, Sławomir Tubek2, Dagmara Poplicha3, Anna Grabelus2, and Jacek Pawelczak2

1Department of Pathophysiology; Medical University; Wroclaw, Poland; 2Department of Internal Diseases; Voivodship Hospital; Opole, Poland

Keywords: Henoch–Schönlein purpura, immunoglobulin treatment, familiar prostatic adenocarcinoma, GI bleeding, diabetes

A 52-y old man was admitted to our department because of abdominal pains and diarrhea with fresh blood, with concomitant purpura over the whole body and edema of the both tarsal joints. The medical history of the patient included skin changes of similar character identified once 10–12 y before. The family history revealed prostate cancer (brother and father) and pulmonary carcinoma (mother and mother’s sister). An administration of immunoglobulins in the course of HSP is a non-standard clinical procedure and in case of our patient—clinically effective. In the literature, we have found only few articles about intravenous immunoglobulin treatment for acute, adult-onset HSP and only one article about GI bleeding from colonic ecchymoses in HSP. In these cases HSP wasn’t associated with prostate cancer. In the first article, authors had seen dramatic responses to intravenous immunoglobulin, like in the case presented by us. IV-IG acts as an immunomodulator by suppression of antibody production, Fc-receptor blockade and anti-idiotypic reaction. In our case, the last two mechanisms could be perceived as favorable effects of IV-IG.

A 52-y old man was admitted to our Department because of abdominal pains and diarrhea with fresh blood, with concomitant purpura over the whole body and edema of the both tarsal joints. The medical history of the patient included skin changes of similar character identified once 10–12 y before. The family history revealed prostate cancer (brother and father) and pulmonary carcinoma (mother and mother’s sister).

On admission, laboratory assays provided normal coagulation parameters—APTT, INR, elevated fibrinogen and D-dimers, decreased antithrombin III levels, increased glucose and HBA1C (9.2) levels and elevated PSA (>150).

Preliminary diagnosis: Bleeding from the lower gastro-intestinal tract; suspected malignancy of the large bowel and of the prostate gland, Henoch–Schönlein purpura (HSP) and first diagnosed type 2 diabetes mellitus.

Insulin and steroid administration completed the mainline treatment.

In the course of hospital observation, purpura progressed to cutaneous purpura over the whole body and edema of the both tarsal joints. The medical history of the patient included skin changes of similar character identified once 10–12 y before. The family history revealed prostate cancer (brother and father) and pulmonary carcinoma (mother and mother’s sister).

An additional, precise, thin-layer thoracic CT revealed no pathologies, except slight fluid volumes in both pleural cavities.

Insulin and steroid therapies were continued, furthermore a broad-spectrum antibiotic therapy was added after the first administration of immunoglobulins in the course of HSP and only one article about GI bleeding from colonic ecchymoses in HSP. In these cases HSP wasn’t associated with prostate cancer. In the first article, authors had seen dramatic responses to intravenous immunoglobulin, like in the case presented by us. IV-IG acts as an immunomodulator by suppression of antibody production, Fc-receptor blockade and anti-idiotypic reaction. In our case, the last two mechanisms could be perceived as favorable effects of IV-IG.

Colonoscopy of the terminal section of the small intestine revealed ulceration with active bleeding and sigmoid diverticulosis. Histopathological results included “Enteritis chronica activa cum ulceratione, tela neoplasmatica absenta” (Chronic enteritis with ulcerations, no presence of neoplastic tissues). CT imaging of the abdominal cavity demonstrated a visible, continually thickened, oedematous wall of the ileum with an excessively enhanced contrast of the mucous membrane—suggestive of inflammatory changes, and oedematous changes in the mesoileum. No tumor was identified. A follow-up CT, performed after two weeks, presented a considerably lower range of oedematous changes within the intestines. Currently, there is a segmental thickening with wall edema in the descending part of the duodenum, in a short section of one of the jejunal loops, as well the cecum and the ascending colon, while the oedematous walls of the ileum, visible in previous imaging, now is only slightly thickened and on a short section with improved mesentary image.

An additional, precise, thin-layer thoracic CT revealed no pathologies, except slight fluid volumes in both pleural cavities.

Insulin and steroid therapies were continued, furthermore a broad-spectrum antibiotic therapy was added after the first CT imaging. Facing a weak response to the applied treatment with deterioration of the general condition of the patient (growing weakness, fever, progression of skin changes and joint pains...
plus maintained diarrhea with blood addition) and low immunoglobulin levels in blood, a decision was made to administer intravenously (i.v.) immunoglobulins (IV-IG)—on the 25th day of hospitalization, a single administration of 20 g of Octagam (human immunoglobulin), 4 times daily a 5-g ampoule of OCTOPHARMA LTD—followed by an evident improvement in the patient’s well-being (within six days, abdominal problems and diarrhea regressed with almost total regression of skin changes, CRP dropped down to 3.6; thrombocythaemia was up to 538 \times 10^3/\text{uL}, and leukocytosis were maintained; the other, above-mentioned parameters, were not controlled during hospitalization before immunoglobulin administration).

Biopsy of the prostatic gland was performed with diagnosis of adenocarcinoma.

The hospitalized patient was consulted by hematologist, rheumatologist, dermatologist and surgeon.

The entire clinical presentation of the described patient suggests the paraneoplastic syndrome in the course of familial prostate carcinoma with positive family history of the condition as well with history of pulmonary neoplasms and type 2 diabetes mellitus—what, accordingly, predisposes to the described changes, typical for HSP. The observed intestinal changes should be treated as HSP symptoms. An administration of immunoglobulins in the course of HSP is a non-standard clinical procedure and in case of our patient–clinically effective.


The patient was referred to the urological center to be qualified for further treatment.

Case study justification:

- family history of prostate cancer in a patient with family history of pulmonary neoplasms and type 2 diabetes mellitus;
- typical for HSP, vascular changes (leukoclastic vasculitis in the course of primary disease, supported by dermatologic counselling) with significant gastric tract involvement;
- a rapid turn after the i.v. immunoglobulin administration toward considerable improvement of the patient’s general well-being, enabling further instituting of diagnostic and therapeutic protocols.

In the literature, we have found only few articles about intravenous immunoglobulin treatment for acute, adult-onset HSP\(^1,2\) and only one paper about GI bleeding from colonic ecchymoses in HSP.\(^3\) In these cases HSP wasn’t associated with prostate cancer. In the first article authors had seen dramatic responses to intravenous immunoglobulin, like in the case presented by us.

IV-IG acts as an immunomodulator by suppression of antibody production, Fc-receptor blockade and anti-idiotypic reaction.\(^4\) In our case, the last two mechanisms could be perceived as favorable effects of IV-IG.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

3. Cappell MS, Onea M, Amin M. GI bleeding from colonic ecchymoses associated with cutaneous ecchymoses over the lower extremities from leukocytoclastic vasculitis mediated by IgA deposition in Henoch–Schönlein purpura. Dig Dis Sci 2011; 56:1919-20; http://dx.doi.org/10.1007/s10620-010-1502-0; PMID:21136164